Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Net Income (2020 - 2025)

Xeris Biopharma Holdings' Net Income history spans 6 years, with the latest figure at $11.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Net Income rose 316.72% year-over-year to $11.1 million, compared with a TTM value of $554000.0 through Dec 2025, up 101.01%, and an annual FY2025 reading of $554000.0, up 101.01% over the prior year.
  • Net Income for Q4 2025 was $11.1 million at Xeris Biopharma Holdings, up from $621000.0 in the prior quarter.
  • The five-year high for Net Income was $11.1 million in Q4 2025, with the low at -$50.8 million in Q4 2021.
  • Average Net Income over 5 years is -$16.7 million, with a median of -$16.3 million recorded in 2023.
  • Year-over-year, Net Income crashed 132.37% in 2021 and then skyrocketed 316.72% in 2025.
  • Tracing XERS's Net Income over 5 years: stood at -$50.8 million in 2021, then soared by 74.54% to -$12.9 million in 2022, then dropped by 3.56% to -$13.4 million in 2023, then surged by 61.81% to -$5.1 million in 2024, then skyrocketed by 316.72% to $11.1 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Net Income are $11.1 million (Q4 2025), $621000.0 (Q3 2025), and -$1.9 million (Q2 2025).